Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin
Response to Farooki and Schneider
- Samantha L. Bowker, MSC1,
- Sumit R. Majumdar, MD, MPH12,
- Paul Veugelers, PHD3 and
- Jeffrey A. Johnson, PHD13
- 1Institute of Health Economics, Edmonton, Alberta, Canada
- 2Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
- 3Department of Public Health Sciences, University of Alberta, Edmonton, Alberta, Canada
- Address correspondence to Dr. Jeffrey A. Johnson, #1200, 10405 Jasper Ave., Edmonton, Alberta, T5J 3N4, Canada. E-mail: jeff.johnson{at}ualberta.ca
Response to Farooki and Schneider
We thank Farooki and Schneider (1) for their comments on our recently published article (2) on diabetes treatments and cancer-related mortality. As we had indicated (2), we agree with Drs. Farooki and Schneider that additional clinical data would aid our understanding of pathophysiologic mechanisms. Clinical intervention studies may be optimal in obtaining such pathophysiologic data. However, such studies may be impractical given the large numbers of patients required …
In this Issue
August 2006, 29(8)
Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin
